The simplicity of CRISPR-Cas9 gene editing will soon make studying the genes of any organism, from the simplest slime mold to the octopus, as easy as it now is to study the genes controlling development in standard lab animals such as nematodes, fruit flies, frogs and mice.
A new study from UC Berkeley illustrates the ease with which CRISPR-Cas9 can knock out genes in exotic animals — in this case, an amphipod or sandhopper — to learn how those genes control growth and development. Researchers wanted to know which genes control the development of appendages on each segment of the amphipod, whose body is like a Swiss army knife with each segment bearing a different blade or tool as an appendage.
In less time than it would have taken two years ago to knock out one gene in the animal, UC Berkeley researchers knocked out six, shedding light on the basic genetic mechanisms that determine leg anatomy in the evolution of animals. By knocking out, one by one, the so-called Hox genes that specify body parts in all animals, they switched the identities of the crustacean’s limbs, transforming a claw into a leg, for example, or a jaw into an antenna.
“For those of us studying non-traditional model organisms in the lab, this has the flavor of a technical revolution,” said UC Berkeley postdoctoral researcher Arnaud Martin. “CRISPR-Cas9 definitely changes the range of possibilities in working with exotic animals, and the amphipod is one of the first.”
The Hox family of genes Martin is investigating is found in all animals, and some biologists argue that an animal can be defined as any creature having Hox genes. They are known to turn on or off a myriad of genes in each segment of the body. Humans’ body segments are most evident in the spine, where each type of spinal vertebra is unique in shape, all under the control of Hox genes.
In the tropical marine amphipod Parhyale hawaiensis, Martin and Patel wanted to know which of the Hox genes function in each of its 19 segments to produce mouthparts at the front, then claws, followed by forward-moving legs, powerful jumping legs that propel the crustacean backwards, swimming legs and finally stumpy “anchor” legs.
“CRISPR-Cas9 has made a huge impact already in model systems, like the fruit fly Drosophila and the nematode C. elegans, where there are already a lot of tools. People were able to incorporate the technology very quickly and change the way they make mutants in those animals,” said senior author Nipam Patel, a UC Berkeley professor of molecular and cell biology and of integrative biology. “But there are a lot of other animals we want to work with because we can use them to answer really basic evolutionary questions. CRISPR-Cas9 is a great technology for that.”
Other researchers have recently used CRISPR-Cas9 to edit genes in unusual organisms like the sea anemone, the lamprey and butterfly to see whether the tool works, but for the most part these have been “proof-of-principle” experiments using CRISPR-Cas9 to confirm what was already known.
“Here we have gone way beyond just showing that it works in Parhyale and jumped right into answering a really important developmental and evolutionary question: how you set up all of these limbs in the crustacean, and how evolution changes that pattern of limbs by altering Hox gene expression patterns,” Patel said.
Read more: CRISPR-Cas9 helps uncover genetics of exotic organisms
The Latest on: CRISPR-Cas9 gene editing
[google_news title=”” keyword=”CRISPR-Cas9 gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR-Cas9 gene editing
- ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreementon May 20, 2024 at 1:43 am
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM ...
- How Gene Editing Therapies Could Go Beyond Rare Diseaseson May 16, 2024 at 6:00 am
In the wake of the first CRISPR medicine, scientists are working to develop gene editing therapies for diseases like cystic fibrosis, ALS and cardiovascular disease.
- Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trialon May 13, 2024 at 1:06 pm
Mass Eye and Ear-led phase 1/2 trial, which included 14 participants, found that the first-of-its-kind experimental treatment was safe and efficacious. BRILLIANCE trial results showed 11 out of 14 ...
- BSM arranges workshop on CRISPR-Cas9 Gene Editing: A new era in molecular biologyon May 12, 2024 at 3:36 am
Bangladesh Society of Microbiologists (BSM) arranged a comprehensive 5-day workshop providing hands-on training on CRISPR experimental design to 20 candidates in the first phase of the workshop ...
- CRISPR gene editing trial treats inherited blindnesson May 9, 2024 at 1:24 am
A British toddler born deaf has become the first person to have their hearing restored via gene therapy. The 18-month-year-old Opal Sandy has been reportedly enjoying playing the drums and babbling ...
- Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindnesson May 8, 2024 at 9:28 am
A newer technology makes use of gene editing with the injection of EDIT-101. It is based on the use of clustered regularly interspaced short palindromic repeats (CRISPR) coupled with the ...
- CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approachon May 8, 2024 at 12:00 am
CTX340™ and CTX450™ utilize LNP-based delivery of CRISPR/Cas9 gene editing cargo to the liver, targeting angiotensinogen (AGT) for refractory hypertension and 5’-aminolevulinate synthase 1 (ALAS1) for ...
- CRISPR gene editing shows promise for treating individuals with a form of inherited blindnesson May 6, 2024 at 12:03 pm
Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the ...
- CRIPSR gene editing leads to improvements in vision for people with inherited blindness, clinical trial showson May 6, 2024 at 9:14 am
Results of a phase 1/2 clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the ...
- CRISPR gene therapy improves vision in people with inherited blindnesson May 6, 2024 at 6:06 am
Phase 1/2 trial of Brilliance showed promising results in vision improvement in people with inherited retinal disorders.
via Bing News